Patents Examined by Timothy R Rozof
  • Neuroprotective quinoline sulfonamides
    Patent number: 11213701
    Abstract: Disclosed herein are methods and compositions comprising compounds capable of activating and increasing protein SUMOylation. Disclosed herein are methods and compositions comprising compounds capable of showing neuroprotective and cytoprotective effects when administered to injured cells. Also disclosed are methods comprising these compounds for treating neuronal or neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, fronto-temporal dementia, chronic traumatic encepholopathy, traumatic brain injury, or stroke.
    Type: Grant
    Filed: December 1, 2019
    Date of Patent: January 4, 2022
    Inventor: Russell Dahl
  • Substituted pyrazolo-pyrazines and their use as GluN2B receptor modulators
    Patent number: 11214563
    Abstract: Substituted PYRAZOLO-PYRAZINES as GluN2B receptor ligands. Such compounds may be used in GluN2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by GluN2B receptor activity.
    Type: Grant
    Filed: June 12, 2020
    Date of Patent: January 4, 2022
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Curt Dvorak, Heather Coate
  • Histone demethylase inhibitors
    Patent number: 11214542
    Abstract: The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted amidopyridine or amidopyridazine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.
    Type: Grant
    Filed: September 18, 2020
    Date of Patent: January 4, 2022
    Assignee: CELGENE QUANTICEL RESEARCH, INC.
    Inventors: Young K. Chen, Toufike Kanouni, Zhe Nie, Jeffrey Alan Stafford, James Marvin Veal, Michael Brennan Wallace
  • Chemical process for preparing phenylpiperidinyl indole derivatives
    Patent number: 11208398
    Abstract: The present invention relates to a method of synthesizing a compound of formula (I) also referred to as 4-((2S,4S)-(4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl))benzoic acid, or a pharmaceutically acceptable salt thereof, and/or intermediates thereof, their use as pharmaceuticals and pharmaceutical compositions and the use of intermediates for preparing a compound of formula (I), or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 15, 2019
    Date of Patent: December 28, 2021
    Assignee: NOVARTIS AG
    Inventors: Peng Fu, Yu Gai, Feng Gao, Weiyong Kong, Yadong Lu, Zhongcheng Min, Shaofeng Rong, Chutian Shu, Can Wang, Ruidong Wang, Jibin Zhao, Xianglin Zhao, Yi Zhao, Jianguang Zhou, Benjamin Martin
  • Method and composition related to combination therapy for addiction
    Patent number: 11207322
    Abstract: Certain embodiments are directed to methods of treating or preventing an addictive behavior in a subject by administering to the subject an effective amount of a 5-HT2C receptor agonist in combination with a DA D3/D4 receptor antagonist.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: December 28, 2021
    Assignee: Board of Regents, The University of Texas System
    Inventors: Charles France, Gregory Collins
  • KCNQ potentiators
    Patent number: 11208383
    Abstract: Small molecule potentiatiors to potassium channels (such as Kv7 potentiators—which are also called KCNQ potentiators), compositions including such compounds, and methods of using such compounds for the treatment of Amyotrophic Lateral Sclerosis and other neurological diseases caused by changes in motor neuron excitability, including, but not limited to, primary lateral sclerosis, pseudobulbar palsy, progressive bulbar palsy, progressive muscular atrophy and epilepsy.
    Type: Grant
    Filed: February 4, 2020
    Date of Patent: December 28, 2021
    Assignee: Eli Lilly and Company
    Inventors: Helen Jane Szekeres, Maria Ann Whatton, Andrew Caerwyn Williams
  • Highly purified pharmaceutical grade tasimelteon
    Patent number: 11203581
    Abstract: A process for preparing a batch of highly purified, pharmaceutical grade tasimelteon comprises analyzing a batch of tasimelteon synthesized under GMP conditions for the presence of one or more identified impurities.
    Type: Grant
    Filed: September 30, 2020
    Date of Patent: December 21, 2021
    Assignee: VANDA PHARMACEUTICALS INC.
    Inventors: Deepak Phadke, Natalie M. Platt, Ravi K. Pandrapragada
  • Istaroxime-containing intravenous formulation for the treatment of acute heart failure (AHF)
    Patent number: 11197869
    Abstract: Compositions for intravenous infusion of istaroxime, or a metabolite of istaroxime, in human patients suffering from heart failure are disclosed. Likewise, methods for extended infusion of istaroxime or its metabolites in individuals with heart failure are disclosed. In particular, some methods disclosed herein include the infusion of istaroxime, or a metabolite thereof, for a period of time that is greater than six hours in order to improve cardiac relaxation without triggering arrhythmogenic events in an individual suffering from heart failure. Other methods include administration of istaroxime until certain plasma concentration thresholds of istaroxime metabolites are achieved. Also disclosed are istaroxime metabolites with selective SERCA2a activation.
    Type: Grant
    Filed: April 16, 2021
    Date of Patent: December 14, 2021
    Assignee: Windtree Therapeutics, Inc.
    Inventors: Giuseppe Bianchi, Patrizia Ferrari, Mara Ferrandi, Paolo Barassi
  • N-aryl oxamic acids
    Patent number: 11192850
    Abstract: The present disclosure relates to novel N-aryl oxamic acid based inhibitors for Mycobacterium tuberculosis protein tyrosine phosphatase B (mPTPB), and to the method of making and using the novel N-aryl oxamic acid based inhibitors. More specifically, compounds provided in this disclosure can be used to inhibit Mycobacterium tuberculosis protein tyrosine phosphatase B (mPTPB) and to treat a patient having a Tuberculosis disease.
    Type: Grant
    Filed: February 1, 2021
    Date of Patent: December 7, 2021
    Assignee: Purdue Research Foundation
    Inventors: Zhong-Yin Zhang, Kasi Viswanatharaju Ruddraraju
  • Methods for enriching alpha-tocotrienol from mixed tocol compositions
    Patent number: 11186559
    Abstract: Provided herein are methods for making an alpha-tocotrienol enriched tocol mixture, such as from a plant or plant-derived material. Also provided herein are simulated moving bed purification methods for tocotrienol compounds such as alpha tocotrienol.
    Type: Grant
    Filed: August 17, 2020
    Date of Patent: November 30, 2021
    Assignee: PTC Therapeutics, Inc.
    Inventors: Peter Giannousis, Paul Mollard, Noah M. Benjamin, Jeffrey D. Butler, Olivier Dapremont, James B. Falabella
  • Substituted cyclic amides and their use as herbicides
    Patent number: 11180453
    Abstract: Disclosed are compounds of Formula 1, N-oxides of the compounds and salts of the compounds and N-oxides: wherein R1, R2, R3, R4, R5, R6, Q1, Q2, J, Y1, and Y2 are as defined in the disclosure. Also disclosed are compositions containing the compounds, N-oxides and salts, and methods for controlling undesired vegetation comprising contacting the undesired vegetation or its environment with an effective amount of such a compound, N-oxide, salt or composition.
    Type: Grant
    Filed: May 15, 2020
    Date of Patent: November 23, 2021
    Assignee: FMC Corporation
    Inventors: Andrew Duncan Satterfield, Matthew James Campbell, James Francis Bereznak, William Guy Whittingham, Glynn Mitchell, Christopher John Mathews, James Nicholas Scutt, James Alan Morris, Jonathan Wesley Paul Dallimore
  • Crystal form of ?-lactamase inhibitor and preparation method therefor
    Patent number: 11180501
    Abstract: Disclosed in the present disclosure are a crystal form of a ?-lactamase inhibitor and a preparation method therefor, as well as an application of the crystal form in preparing a ?-lactamase inhibitor drug.
    Type: Grant
    Filed: December 3, 2018
    Date of Patent: November 23, 2021
    Assignee: QILU PHARMACEUTICAL CO., LTD.
    Inventors: Cheng Li, Zhigang Huang, Charles Z. Ding, Weidong Li
  • Treatment of nonalcoholic fatty liver disease
    Patent number: 11179384
    Abstract: The present invention is directed to methods for the treatment of non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steato-hepatitis (NASH) with a phosphodiesterase 4 (PDE4) inhibitor.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: November 23, 2021
    Assignee: TAKEDA GMBH
    Inventors: Guido Hanauer, Hiroshi Nagabukuro, Yuichiro Amano
  • 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases
    Patent number: 11174272
    Abstract: The present invention provides a compound useful as an agent for the prophylaxis or treatment of neurodegenerative disease and the like, or a salt thereof. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Grant
    Filed: July 20, 2020
    Date of Patent: November 16, 2021
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Tatsuki Koike, Masato Yoshikawa, Haruhi Ando, William John Farnaby
  • Crystal form of 4-phenylthiazole derivative and preparation method thereof
    Patent number: 11174234
    Abstract: The invention relates to a crystal form of 4-phenylthiazole derivative, a pharmaceutical composition comprising the same, a preparation method, and a use of the crystal form for the manufacture of a medicament for treating thrombocytopenia.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: November 16, 2021
    Assignee: Sichuan Kelan Pharmaceutical Research Institute Co., Ltd.
    Inventors: Shidong Yi, Zheng Gong, Tianming Wang, Chengxi Yang, Lichun Wang, Jingyi Wang
  • Crystal form of 3,4-dihydrothieno[3,2-d]pyrimidine compound and preparation method thereof
    Patent number: 11174270
    Abstract: A crystal form A of a 3,4-dihydrothieno[3,2-d]pyrimidine compound (1), a preparation method therefor and an application thereof in the preparation of an anti-human cytomegalovirus (HCMV) drug.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: November 16, 2021
    Assignee: Phaeno Therapeutics Co., Ltd.
    Inventors: Jian Xiong, Jingjing Wang, Boyu Hu, Haizhong Tan, Kevin X. Chen, Jian Li, Shuhui Chen
  • Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity
    Patent number: 11166936
    Abstract: This disclosure provides methods and pharmaceutical compositions for reducing or eliminating cardiotoxicity, particularly cardiotoxicity induced by a cancer treatment or other therapy. In some cases, the methods and compositions prevent or reduce cardiotoxicity caused by anthracycline treatment. The methods provided herein often comprise administering a protective agent such as myricetin, tricetin, robinetin, ficetin, vitexin, quercetin, dihydrorobinetin, kaempferol, 7,3?,4?,5?-tetrahydroxyflavone, and myricitrin in conjunction with the administration of a cancer drug or other treatment. They may comprise administering a protective agent in combination with dexrazoxane. The compositions provided herein include co-formulations of a protective agent with a different protective agent or with a cancer treatment (e.g., anthracycline drug).
    Type: Grant
    Filed: October 6, 2020
    Date of Patent: November 9, 2021
    Assignees: Auransa Inc., SCT II LLC
    Inventors: Christopher G. Armstrong, Kevin J. Kim, Lisa Maria Lucia Pham, Eunhye Park, Zhong Zhong, Guanyi Huang, Joseph C. Wu, Sidney Paul Elmer, Viwat Visuthikraisee, Eithon Michael G. Cadag, Thomas Bernard Freeman, Pek Yee Lum
  • Endocyclic thiamidinoamide-arylamide compound and use thereof for treating hepatitis B
    Patent number: 11168055
    Abstract: Disclosed are an endocyclic thiamidinoamide-arylamide compound and a pharmaceutical composition comprising the compound described above, and the use of the compound or pharmaceutical composition in the treatment of hepatitis B. In particular, disclosed is a compound that can be used as an HBV replication inhibitor and has the structure as shown in chemical formula (L), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate or solvate thereof.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: November 9, 2021
    Assignee: SHANGHAI LONGWOOD BIOPHARMACEUTICALS CO., LTD.
    Inventors: Zhe Wang, Xiaoguang Wang, Sai Yang, Zhihong Zeng
  • Inhibiting the transient receptor potential al ion channel
    Patent number: 11161849
    Abstract: The present invention relates to pharmaceutical compounds of the Formula (I), or a pharmaceutically acceptable salt or composition thereof, and methods of their use for the treatment of pain, respiratory conditions, as well as inhibiting the Transient Receptor Potential A1 ion channel (TRPA1).
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: November 2, 2021
    Assignee: Eli Lilly and Company
    Inventor: Xinyuan Edward Wu
  • Quinoline derivative and use thereof as tyrosine kinase inhibitor
    Patent number: 11161817
    Abstract: A quinoline derivative compound shown in formula (II), a pharmaceutically acceptable salt thereof, and an application of the same in preparing a drug for treating a disease related to a tyrosine kinase inhibitor.
    Type: Grant
    Filed: September 20, 2018
    Date of Patent: November 2, 2021
    Assignees: CHONGQING PHARMACEUTICAL INDUSTRIAL RESEARCH INSTITUTE CO. LTD., YAOPHARMA CO., LTD.
    Inventors: Yang Zhang, Zhengxia Chen, Meibi Dai, Wenju Li, Jian Li, Shuhui Chen